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Abstract Puberty suppression by means of gonadotropin
releasinghormone(GnRH)analogsisconsideredadiagnosticaid
ingenderdysphoricadolescents.However,therearealsoconcerns
aboutpotentialrisks,suchaspooroutcomeorpost-surgicalregret,
adverseeffectsonmetabolicandendocrinestatus,impairedincre-
mentofbonemass,andinterferencewithbraindevelopment.This
case report is on a 22-year follow-up of a female-to-male trans-
sexual, treated with GnRH analogs at 13years of age and con-
sidered eligible for androgen treatment at age 17, and who had
genderreassignmentsurgeryat20and22yearsofage.Atfollow-
up, he indicated no regrets about his treatment. He was function-
ingwellpsychologically,intellectually,andsocially;however,he
experienced some feelings of sadness about choices he hadmade
inalong-lastingintimaterelationship.Therewerenoclinicalsigns
of a negative impact on brain development. He was physically in
goodhealth,andmetabolicandendocrineparameterswerewithin
reference ranges. Bone mineral density was within the normal
range for both sexes. His ﬁnal height was short as compared to
Dutch males; however, his body proportions were within normal
range.Thisﬁrstreportonlong-termeffectsofpubertysuppression
suggests that negative side effects are limited and that it can be a
useful additional tool in the diagnosis and treatment of gender
dysphoric adolescents.
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Introduction
In1998,acasestudywaspublisheddescribingtheuseofa
gonadotropin releasing hormone (GnRH) analog to suppress
pubertyofa13-year-oldgender-dysphoricgirl(Cohen-Kettenis
&v a nG o o z e n ,1998). At age 16, she was referred to a gender
identity clinic where a diagnosis of gender identity disorder
(GID)wasmade.Shewasconsideredeligibleforandrogentreat-
ment at age 17, but chose to delay the therapy and social transi-
tioning until she was 18years old, because she ﬁrst wanted to
ﬁnish high school. Subsequently, she had gender reassignment
surgery. This case illustrated that puberty suppression may be
useful as an additional tool in the diagnosis and treatment of
young gender dysphoric adolescents and that, for certain ado-
lescentswithalife-longconsistentandextremeGID,itmaybea
physically and psychologically beneﬁcial way to intervene.
Sincethisﬁrstcase,GnRHanalogprescriptionhasbeenintro-
ducedasapartofanextendeddiagnosticphaseonamoreregular
basis at the Dutch clinic where she had been treated. The way it
was used in the diagnostic protocol has been described in detail
elsewhere(Cohen-Kettenis&Pfa ¨fﬂin,2003;Cohen-Kettenis&
Delemarre-van de Waal, 2006). In the last decade, puberty sup-
pression has become part of the gender reassignment procedure
inanumberofclinicsinEuropeancountries,Australia,Canada,
and the U.S.
As has been argued previously, puberty suppression in gen-
der dysphoric adolescents hasa number of advantages(Cohen-
Kettenis,Delemarre-vandeWaal,&Gooren,2008;Wren,2000).
First, it may relieve the suffering that stems from a discrep-
ancybetweenone’sassignedandexperienced/expressedgender,
whichcanadverselyaffectone’ssocialdevelopmentandschool
career. Second, adolescents and mental health professionals
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deridentitydevelopmentandtheirdesireforgenderreassignment.
Third,GnRHanalogtreatedadolescentswithpersistingGIDwill,
as adults, have fewer problems in passing in the new gender than
untreatedadolescents,whichmaycontributetobetteradjustment
(Nuttbrocketal.,2010;Ross&Need,1989).Fourth,pubertalsup-
pression makes certain forms of surgery redundant or less inva-
sive.Fifth,unfavorablepostoperativeoutcomeseemstobeassoci-
ated with a late rather than an early start of gender reassignment
(forreviews,seeCohen-Kettenis&Gooren,1999;Pfa ¨fﬂin&
Junge,1992).Sixth,youthwithoutaccesstothistreatmentmay
try to ﬁnd illicit sources of medication (e.g., the Internet).
Resistancetopubertalsuppressionalsoexists.Somecon-
sider it impossible to make a deﬁnitive diagnosis of GID in
adolescence,becausetheybelievethatgenderidentitymaystill
be ﬂuctuating during this developmental phase (Korte et al.,
2008;Viner,Brain,Carmichael,&DiCeglie,2005).However,
GIDinadolescenceappearstobehighlypersistent.AttheDutch
gender identity clinic, none of the adolescents diagnosed with
GID and treated with GnRH analogs refrained from further
treatment procedures or regretted gender reassignment. Those
who could not start treatment immediately after completion of
the diagnostic procedure because of serious risk factors did not
refrain from pursuing gender reassignment later. They usually
started treatment after the other issues had been addressed,
which was, in some cases, in early adulthood.
Another important point of criticism concerns the physical
consequences of GnRH analogs on the development of bone
mass, growth, and brain development. The ﬁrst data of a Dutch
cohortofadolescentswhohadbeentreatedwithGnRHanalogs
suggest that, after an initial slowing in bone accretion, it sig-
niﬁcantly caught up after the commencement of cross-sex ste-
roid hormone treatment (Delemarre-van de Waal & Cohen-
Kettenis,2006).Bodyproportions,asmeasuredbysittingheight
and sitting-height/height ratio, remained in the normal range.
With regard to height, for both genders, stature could be inﬂu-
enced hormonally to become more in the range of the desired
sex (Delemarre-van de Waal & Cohen-Kettenis, 2006).
Since most of the adolescents who were treated with GnRH
analogs are still in their early 20s, psychological and physical
long-term effects of puberty suppression are not known. This
report is the ﬁrst very long-term follow-up (22years) of a natal
female, now35yearsold, whounderwent pubertalsuppression
and subsequent gender reassignment. He read the report and
provided us with a letter of consent to publish it.
Case Report
First Follow-Up: Psychosocial Information
In the 1998 reporton the treatment of B, he was 20years old. B
hadbeenachildwithaclassicalgenderdysphoricdevelopment
and fulﬁlled the current criteria for GnRH analog treatment eli-
gibility.Hewasinterviewedshortlyafterhislegalgenderchange.
This meant that he had had puberty suppression, cross-sex hor-
mone treatment, a mastectomy, ovariectomy, and uterus extir-
pation. From his assessment during the diagnostic phase, he
appeared to be an intelligent person (IQ=128) with excellent
problem-solving capabilities with respect to emotional matters.
Vulnerable aspects of his psychological functioning were his
insecurityabouthimselfandmoderatelydepressedfeelings.Inall
other areas, his scores on a broad range of measures were in the
averagerange,ascomparedtoDutchnormativesamples.Shame
concerning his transsexualism made him highly selective in his
friendships and guarded in his contacts with new people. At the
assessment, 1year after his ovariectomy but prior to his meta-
idoioplasty, he no longer reported feelings of gender dysphoria.
He had adjusted easily to the male role and expressed no doubts
on the adequacy of his masculine behavior. After the develop-
ment of his secondary male sex characteristics, nobody had ever
approached him as a woman. He never felt any regrets about his
decisionandhadnevercontemplatedlivingasagirlagain.Know-
ing what gender reassignment implied, he would do it all over
again. B was happy with his life and did not feel lonely. He
showedasigniﬁcantpre-posttreatmentdecreaseinhisfeelings
of inadequacy. At the time, he was attending medical school.
First Follow-Up: Medical Information
B attended the pediatric endocrinology clinic for the ﬁrst time
when he was age 13.7years. His medical history was unevent-
ful.Pubertyhadstarted1–2yearspreviously,butmenarchehad
not occurred. On physical examination, a healthy girl was seen
withaheightof157.3cmandaTannerpubertalstageofB3,P3.
Bone age according to Tanner and Whitehouse was 13.5years.
Targetheight,asafemale,wasestimatedat171cm,basedonthe
parentalheight.PubertysuppressionwasinducedbytheGnRH
analog Triptorelin, in a dose of 3.75mg every 4weeks intra-
muscularly. On this dosage, B steadily kept on growing.
Atage18.6years,hisheightwas165.8cm.Inductionofmale
puberty and accompanying secondary male sex characteristics
was initiated by administration of 100mg testosterone-ester
mixtureintramuscularlyevery2weeks.Thiswas,after6months,
increased to 250mg testosterone-ester mixture, every 2–3
weeksintramuscularly.Atthestartoftheandrogentreatment,
the Triptorelin treatment was discontinued.
When B was 20years old, he had a subcutaneous mastec-
tomy by way of an infra-areolar approach, a few months later
followedbyahysterectomyandgonadectomy.Twoyearslater,
metaidoioplasty and testes implantation were performed.
Second Follow-Up: Psychosocial Information
Fifteen years after the ﬁrst interview and testing session, at age
35, B was seen again at the clinic. He lived on his own and he
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leagues.Allfamilymembersknewabouthistransitioningasdid
some of his friends. He was very satisﬁed about his circle of
friends and had never been treated negatively because of his
transsexualism.
Bwasstillsatisﬁedabouthis(minor)breastsurgery,hisovar-
iectomy, and his hysterectomy, but no longer about the meta-
idoioplasty he underwent one year after the ﬁrst follow-up
session. He did not like its size and shape and he could hardly
urinateinastandingposition.Hewasabletohaveorgasms,but
he could not have sexual intercourse. Because of his desire to
have more convincingly male appearing external genitals and
his wish to be able urinate in a standing position, he considered
having a phalloplasty. Despite his good looks and very mascu-
lineappearance, he had nothad many steady girlfriends, which
may have resulted from the guardedness he already had as
an adolescent. At age 29, he had a serious relationship with a
woman,whichlastedfor5years.However,hechosenot tolive
togetherwhentheopportunitytodosoarose.Afterhischoiceto
continuelivingapart,hisgirlfriendendedtherelationship,afew
months before his interview at the clinic. This made him very
muchregrethislackofcommitment.Bconsidereditlikelythat
his need to distance himself from her had been related to his
shame about his genital appearance and his feelings of inade-
quacy in sexual matters. Additional factors, such as serious ill-
nessofhisfatherandasuicideamonghissisters’in-laws,made
him rather sad at the time of the interview. Although his psy-
choneuroticism score on the Symptom Checklist-90 (Arrindell
& Ettema, 2003) was in the normal range, his depression sub-
score was high, indicating depressed feelings. However, on the
Beck Depression Inventory, he scored in the‘‘minimal range’’
(van der Does, 2002), indicating that he did not fulﬁll criteria
forclinicaldepression.OntheAdultSelf-Report,assessing
adaptivefunctioningandproblemsinadultsaged18-59years
(Achenbach & Rescorla, 2003), all his scores were in the
normal range.
It seems, therefore, that B functioned well in most aspects of
life,butthathewasstillstrugglingwiththequestion,howtohandle
the dissatisfaction and shame about his genital appearance.
Second Follow-Up: Medical Information
At age 35, on physical examination, we saw a healthy and well
virilizedperson.Bloodpressurewas120/85mmHg,ﬁnalheight
was 169.5cm and weight was 73kg, which resulted in a body
massindex(BMI)of25.4kg/m
2.Sittingheightwas88cm.Skull
circumference was 55.5cm. For a comparison of his anthro-
pometrical measurements to the normal reference values of
Dutch males and females, see Table1.
Test Results
A fasting venous blood sample was drawn. General health
markers, like hematological parameters (Hb, ht, erythrocytes),
renalfunction,andliverenzymes,wereallwithinthenormalref-
erencevalueranges.Hislipidproﬁleshowedatotalcholesterol
levelof228.3mg/dl(\251.5mg/dl),LDL-cholesterol154.8mg/
dl (\193.5mg/dl), HDL-cholesterol 55.0mg/dl ([34.8mg/dl),
andtriglycerides97.4mg/dl(\177mg/dl).Hisglucosevaluewas
97.3mg/dl (\144.1mmol/l) with an insulin level of 21pmol/l
(12–96pmol/lforafastingsample).HisHbA1cwas5.4%(4.3–
6.1%). These values were in the normal range.
With respect to the gonadal axis, a normal-low serum tes-
tosterone level of 236.6ng/dl (231–866ng/dl) was found. This
relatively low level was probably due to the fact that the blood
samplewastakenjustbeforethenexttestosterone-estermixture
injection.Gonadotropinswereelevatedasaconsequenceofthe
gonadectomy.LH andFSH were16U/land50U/l,respec-
tively.Additionallydeterminedendocrineparameters,suchas
thyroidandadrenalfunction,wereallwithinnormalreference
ranges.
With respect to bone mineral density (BMD), a dual energy
X-ray absorptiometry (DEXA) scan was performed to deter-
mine B’s BMD in the lumbar spine, the non-dominant hip, and
(further) total body. The observed values were related to the
bonepeakmassforwhitefemalesandforwhitemales,resulting
in T-scores. For all values, the z-score was determined as well
(see Table2).
Table1 B’santhropometricalmeasurementsatthetimeofhislastvisittoouroutpatientclinic(age35)comparedtoDutchreferencevaluesforboth
sexes
B SD females P50 females SD males P50 males
Height (cm) 169.5 -0.16 170.56 -2.03 183.86
Weight (kg) 73 0.95 63.85 -0.24 75.28
Sitting height (cm) 88 -0.47 89.63 -1.94 94.65
Sitting height/height ratio 0.519 -0.47 0.5260 0.02 0.5130
Skull circumference (cm) 55.5 0.13 55.29 -1.32 57.82
BMI (kg/m
2) 25.4 1.93 22.90 1.90 22.11
SD standard deviation, P50 50th percentile
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The case of B is the ﬁrst in the literature to show the long-term
resultsofpubertysuppressionandsubsequenthormonaland
surgicalinterventioninaconsistentlygenderdysphoricyouth.
Suppression of puberty in adolescents should be done only
aftercarefuldiagnosticworkbyspecialistsintheﬁeld.Giving
informedconsentisacrucialaspectoftheprocedure.Inorder
togivevalidconsent,theadolescentshouldhave,ascompletely
as possible, information about known and unknown aspects of
the treatment. In the case of B, it was not possible to give the
13yearadolescentmuchinformationonthelong-termeffectsof
GnRH analog treatment in physically healthy young people.
Yet,Bwascertainthathedidnotwantanyfurtherpubertaldevel-
opment and very deliberately decided to start with the GnRH
analogs. For anumber ofyears, stillliving in the female role, B
took the opportunity to ﬁgure out whether he truly wanted to
have gender reassignment, knowing that this would not be an
easy life. Although he tended to be embarrassed about his gen-
derdysphoria,especiallyinthebeginningoftheprocess,hehas
always been quite clear about his feeling that he could not live
further as a girl. Twenty-two years after this decision, he still is
convinced that his choice to live as a man was the right one.
The concern of many clinicians that halting puberty for a
numberofyearswouldinvolveunacceptablehealthrisksturned
out not to be true for B. All observed anthropometric measure-
mentswerewithinthenormalrange(50thpercentile±2SD)for
biological females. Also, B’s ﬁnal height was within the target
height range for females. When compared to natal males, how-
ever,B’sﬁnalheightwasjustbelow-2SD.Inallotherrespects,
B’s anthropometric values were in the low-normal male range.
It is noteworthy to realize that the normal values we have used
came from Dutch population studies. As B is half Italian, they
could also be compared to values for inhabitants from Italy,
which deviate from those of the Dutch normal population. The
50th percentile values for height for the Italian population are
163.2cm and 176.9cm for females and males, respectively
(Cacciari et al., 2002). As B’s sitting height/height ratio is near
the50thpercentileforbothsexes,B’sbodyproportioniswithin
the normal range. Blood tests showed increased serum levels
of FSH and LH, which was due to his gonadectomy. B’s lipid
proﬁledidnotdeviatefromthenormalreferencevaluesandthe
BMD measurements showed values well above the 50th per-
centileforbiologicalfemales.Comparedtoreferencevaluesfor
white males, his BMD values were around the 50th percentile.
Although B would have liked to be taller, we did not ﬁnd
unfavorable medical outcomes. Therefore, the fear that GnRH
analogtreatmentwillresultinpoorlong-term outcomewasnot
supportedinthiscase.Nonetheless,long-termfollow-upstudies
on larger cohorts of transgender adults treated with GnRH
analogs are needed to support this ﬁnding.
Although gender reassignment is highly effective in reliev-
inggenderdysphoria(Cohen-Kettenis&Gooren,1999;Gijs&
Brewaeys,2007;Pfa ¨fﬂin&Junge,1992),itisnopanacea.Espe-
cially in the area of intimate relationships, it may remain difﬁ-
cult to ﬁnd a suitable partner and overcome one’s own barriers,
as is shown in the case of B.
Pubertal suppression, however, averts the despair of gender
dysphoric adolescents because of their physical changes and it
may contribute to more self-conﬁdence when socially interact-
ing in adolescence and adulthood. On a day-to-day basis, B did
not have to explain himself or defend his choices. He was not
harassedorstigmatized.ThecaseofBgiveshopethatnegative
sideeffectsofpubertysuppressionarelimited,althoughthe
resultswillhavetobeconﬁrmedinfurtherstudies.Withregard
tothepsychologicalfunctioningofpubertysuppressedandsub-
sequently gender reassigned individuals, a relatively favorable
outcome(atleastoneyearpost-surgery)wasalsorecently
reported(deVries,2010).ThisandB’ssecondfollow-upagain
illustratethatpubertysuppressioncanbeausefuladditionaltool
inthediagnosisandtreatmentofgenderdysphoricadolescents.
This view is supported in the recently published guidelines of
the Endocrine Society on the treatment of transsexual persons
(Hembree et al., 2009).
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